Korean regulator eases up on biotech accounting issues


South Korea's financial regulator said today it will give biotechnology and pharmaceutical firms leeway on listing rules, after allowing them to voluntarily restate accounting errors. Choi Jong Ku, chairman of the Financial Services Commission, said promising biotechnology and pharmaceutical firms will not be designated by the Korea Exchange as an "administrative issue" even if the... South Korea's financial regulator said today it will give biotechnology and pharmaceutical firms leeway on listing rules, after allowing them to voluntarily restate accounting errors.



from Biotech News